Unlocking TIL Therapy: A New Era for Melanoma Care in the UK
TIL (Tumour-Infiltrating Lymphocyte) therapy is a transformative, cell-based immunotherapy approach now entering clinical practice for melanoma. This national summit brings together UK and international leaders to share the science, clinical experience, and infrastructure required to implement TIL therapy safely and effectively. From the biological rationale to real-world delivery, the day explores how academic, clinical, and industry partners can work together to make TIL therapy accessible for patients across the UK.
Intended Audience
Clinical Staff (including Clinical/ Medical Oncologists Surgeons, Haematologists, Pathologists, radiologists), Scientists, Translational Researchers, NHS Policymakers and those who have an interest in this field.
What to expect
– Recognise how biomarkers and the tumour microenvironment predict TIL response
– Understand the core science and clinical development of TIL therapy
– Learn key factors in patient selection, team coordination, and toxicity management.
– Identify challenges in scaling TIL therapy across the NHS